Deborah R Gustafson1, Ingmar Skoog, Lars Rosengren, Henrik Zetterberg, Kaj Blennow. 1. The Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden. deb.gustafson@neuro.gu.se
Abstract
BACKGROUND: Low levels of cerebrospinal fluid (CSF) beta-amyloid 1-42 (Abeta42) and high total tau (T-tau) are diagnostic for manifest Alzheimer's disease. It is not known, however, whether these biomarkers may be risk indicators for cognitive decline in otherwise healthy older people. METHODS: The longitudinal relationship between CSF markers, Abeta42 and T-tau, measured in 1992, and change in Mini-Mental State Examination (deltaMMSE) score between 1992 and 2002 were investigated in 55 women (aged 70-84 years, mean (SD) MMSE score = 28.3 (1.5)), who were participants in the Prospective Population Study of Women in Gothenburg, Sweden. These women did not have dementia when they experienced lumbar puncture in 1992-3. RESULTS: Over the 8-year follow-up period, deltaMMSE (range = +3 to -21 points) was correlated with Abeta42 (Spearman's r = 0.40, p = 0.002), such that lower levels of Abeta42 were related to greater decline. This was also observed after excluding 4 women who developed dementia between 1992 and 2002 (Spearman's r = 0.34, p = 0.019). A multivariate logistic regression model predicting a decline of > or = 5 points on the MMSE (observed in six women), or a risk of developing dementia over the 8-year follow-up period (observed in four women), including age, education, Abeta42 and T-tau as covariates, showed that Abeta42 was the sole predictor of significant cognitive decline or dementia (OR per 100 pg/ml Abeta42 = 2.24, 95% CI 1.19 to 4.22, p = 0.013). CONCLUSIONS: Low levels of CSF Abeta42 may predict cognitive decline among older women without dementia.
BACKGROUND: Low levels of cerebrospinal fluid (CSF) beta-amyloid 1-42 (Abeta42) and high total tau (T-tau) are diagnostic for manifest Alzheimer's disease. It is not known, however, whether these biomarkers may be risk indicators for cognitive decline in otherwise healthy older people. METHODS: The longitudinal relationship between CSF markers, Abeta42 and T-tau, measured in 1992, and change in Mini-Mental State Examination (deltaMMSE) score between 1992 and 2002 were investigated in 55 women (aged 70-84 years, mean (SD) MMSE score = 28.3 (1.5)), who were participants in the Prospective Population Study of Women in Gothenburg, Sweden. These women did not have dementia when they experienced lumbar puncture in 1992-3. RESULTS: Over the 8-year follow-up period, deltaMMSE (range = +3 to -21 points) was correlated with Abeta42 (Spearman's r = 0.40, p = 0.002), such that lower levels of Abeta42 were related to greater decline. This was also observed after excluding 4 women who developed dementia between 1992 and 2002 (Spearman's r = 0.34, p = 0.019). A multivariate logistic regression model predicting a decline of > or = 5 points on the MMSE (observed in six women), or a risk of developing dementia over the 8-year follow-up period (observed in four women), including age, education, Abeta42 and T-tau as covariates, showed that Abeta42 was the sole predictor of significant cognitive decline or dementia (OR per 100 pg/ml Abeta42 = 2.24, 95% CI 1.19 to 4.22, p = 0.013). CONCLUSIONS: Low levels of CSF Abeta42 may predict cognitive decline among older women without dementia.
Authors: F H Bouwman; S N M Schoonenboom; W M van der Flier; E J van Elk; A Kok; F Barkhof; M A Blankenstein; Ph Scheltens Journal: Neurobiol Aging Date: 2006-06-19 Impact factor: 4.673
Authors: C Bengtsson; G Blohmé; L Hallberg; T Hällström; B Isaksson; K Korsan-Bengtsen; G Rybo; E Tibblin; G Tibblin; H Westerberg Journal: Acta Med Scand Date: 1973-04
Authors: I Skoog; P Davidsson; O Aevarsson; H Vanderstichele; E Vanmechelen; K Blennow Journal: Dement Geriatr Cogn Disord Date: 2003 Impact factor: 2.959
Authors: H Hampel; S J Teipel; T Fuchsberger; N Andreasen; J Wiltfang; M Otto; Y Shen; R Dodel; Y Du; M Farlow; H-J Möller; K Blennow; K Buerger Journal: Mol Psychiatry Date: 2004-07 Impact factor: 15.992
Authors: D Galasko; L Chang; R Motter; C M Clark; J Kaye; D Knopman; R Thomas; D Kholodenko; D Schenk; I Lieberburg; B Miller; R Green; R Basherad; L Kertiles; M A Boss; P Seubert Journal: Arch Neurol Date: 1998-07
Authors: K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel Journal: Neurology Date: 2002-08-27 Impact factor: 9.910
Authors: A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark Journal: Neurology Date: 2010-08-18 Impact factor: 9.910
Authors: Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski Journal: Brain Date: 2015-07-27 Impact factor: 13.501
Authors: Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield Journal: Biochim Biophys Acta Date: 2013-10-09
Authors: Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow Journal: Exp Neurol Date: 2009-10-06 Impact factor: 5.330
Authors: John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun Journal: Ann Neurol Date: 2010-01 Impact factor: 10.422
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182